Sanofi SA
SNY
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
Can you achieve global diversification with multinational companies?
A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,945.20 | 66.70 | 0.75% |
| CAC 40 | 8,244.28 | 71.17 | 0.87% |
| DAX 40 | 25,257.27 | 72.38 | 0.29% |
| Dow JONES (US) | 50,614.30 | 152.62 | 0.30% |
| FTSE 100 | 10,505.30 | 13.91 | 0.13% |
| HKSE | 25,328.23 | 271.22 | -1.06% |
| NASDAQ | 26,669.88 | 13.70 | 0.05% |
| Nikkei 225 | 64,999.41 | 3.32 | 0.01% |
| NZX 50 Index | 13,227.81 | 158.07 | 1.21% |
| S&P 500 | 7,522.60 | 3.48 | 0.05% |
| S&P/ASX 200 | 8,717.70 | 65.50 | 0.76% |
| SSE Composite Index | 4,093.73 | 51.65 | -1.25% |